Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes

Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mazhar Hussain, Asim Elahi, Abid Hussain, Javed Iqbal, Lubna Akhtar, Abdul Majid
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2021/9973862
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
by: Takuya Oyakawa, et al.
Published: (2025-01-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
by: Anastasia D. Egorova, et al.
Published: (2022-06-01)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2018-01-01)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
by: Kris Aubrey-Bassler, et al.
Published: (2019-02-01)

Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
by: Eun Hyung Cho, et al.
Published: (2018-01-01)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
by: Jun Muneuchi, et al.
Published: (2022-01-01)

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care
by: Dong-Dong Wang, et al.
Published: (2022-01-01)

Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
by: Kyoung Hwa Ha, et al.
Published: (2025-02-01)

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01)

Optimización SGLT2 para cardionefro protección
by: Yukiko Harumi Yamasaki Ramos, et al.
Published: (2025-01-01)

The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports
by: Yufi Aulia Azmi, et al.
Published: (2025-01-01)

Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
by: Go Anan, et al.
Published: (2023-11-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
by: Qasim Zafar Iqbal, et al.
Published: (2020-01-01)

Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
by: Aongus O’Brolchain, et al.
Published: (2024-01-01)

Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging
by: Agena Suzuki, et al.
Published: (2024-08-01)

Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
by: Yang Hu, et al.
Published: (2020-01-01)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
by: Wenjun Sha, et al.
Published: (2020-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
by: Xiaoyan Liang, et al.
Published: (2025-01-01)

Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective
by: Pendar Farahani
Published: (2018-01-01)

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors
by: Betül SÜMBÜL ŞEKERCİ, et al.
Published: (2025-01-01)

Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials
by: Ying Liu, et al.
Published: (2025-01-01)

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
by: Kazuo Kobayashi, et al.
Published: (2021-01-01)

Correlation Between Serum Uric Acid, Insulin and Hba1c In Type 2 Diabetes Mellitus
by: Maryam Imtiaz, et al.
Published: (2024-06-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Lu Ding, et al.
Published: (2020-01-01)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
by: Ranin Saad, et al.
Published: (2022-01-01)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
by: Vasiliki Tsampasian, et al.
Published: (2021-01-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care
by: Agnieszka Parfianowicz, et al.
Published: (2025-02-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Uric Acid: A Potential Marker For Predicting Maternal And Fetal Morbidity
by: Aeman Javed, et al.
Published: (2024-09-01)

Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin
by: Yu-Hsiang Lin, et al.
Published: (2025-02-01)